General
Preferred name
NINTEDANIB
Synonyms
BIBF-1120, Nintedanib Esylate ()
NINTEDANIB ESYLATE ()
BIBF 1120 ()
Intedanib ()
Nintedanib Ethanesulfonate Salt ()
BIBF 1120 (esylate) ()
BIBF 1120 (esylate)Nintedanib esylate ()
Bibf1120 (Vargatef) ()
Z-Nintedanib (BIBF 1120) ()
Intedanib, Vargatef, Ofev ()
Intedanib, BIBF 1120 ()
Nintedanib (BIBF 1120) ()
BIBF-1120 ()
BIBF1120 ()
OFEV ()
Vargatef ()
BIBF 1120-13C-d3 ()
Nintedanib component of ofev ()
Nintedanib ethanesulfonate ()
Nintedanib esilate ()
Nintedanib accord ()
NINTEDANIB COMPONENT OF OFEV ()
P&D ID
PD003643
CAS
928326-83-4
656247-17-5
656247-18-6
Tags
available
drug
obsolete probe
Approved by
EMA
PMDA
FDA
First approval
2014
Drug Status
approved
Max Phase
4.0
Drug indication
systemic scleroderma
Neoplasm
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Nintedanib is an kinase inhibitor, targeting three arms of proangiogenic signalling via VEGFRs, PDGFR and FGFR .
DESCRIPTION Nintedanib is a kinase inhibitor, targeting three arms of proangiogenic signalling via VEGFRs, PDGFR and FGFR . It was developed by Boehringer Ingelheim.
Marketed formulations contain nintedanib esylate (PubChem CID 135476717). (GtoPdb)
DESCRIPTION Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFR¦Á/¦Â with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
PRICE 54
DESCRIPTION Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFR??, and PDGFR?? (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
DESCRIPTION Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFR¦Á/¦Â with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.
PRICE 54
DESCRIPTION Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFR??/??.
DESCRIPTION inhibitor of c-KIT, VEGFRs, PDGFRs, and FGFRs (Informer Set)
DESCRIPTION Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). (PKIDB)
DESCRIPTION Dual cdk4/cdk6 inhibitor; orally bioavailable (Tocris Bioactive Compound Library)
DESCRIPTION Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer. (Enamine Bioactive Compounds)
DESCRIPTION Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis. (TargetMol Bioactive Compound Library)
DESCRIPTION Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β. (TargetMol Bioactive Compound Library)
Cell lines
8
Organisms
0
Compound Sets
30
AdooQ Bioactive Compound Library
A10137
A16197
Axon Medchem Screening Library
2648
Cayman Chemical Bioactives
11022
31082
25312
ChEMBL Approved Drugs
CHEMBL502835
CHEMBL3039504
ChEMBL Drugs
CHEMBL502835
CHEMBL3039504
Clinical kinase drugs
Concise Guide to Pharmacology 2017/18
5936
Concise Guide to Pharmacology 2019/20
5936
Concise Guide to Pharmacology 2021/22
5936
Concise Guide to Pharmacology 2023/24
5936
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB09079
DrugBank Approved Drugs
DB09079
DrugCentral
4903
DrugCentral Approved Drugs
4903
Enamine Bioactive Compounds
EBC-11367
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
EUB0001907
Guide to Pharmacology
5936
Informer Set
628601
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL502835
CHEMBL3039504
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL502835
CHEMBL3039504
MedChem Express Bioactive Compound Library
HY-50904
HY-11106
NCATS Inxight Approved Drugs
G6HRD2P839
Obsolete Compounds
intedanib
PKIDB
Selleckchem Bioactive Compound Library
BIBF1120
nintedanib-ethanesulfonate-salt
TargetMol Bioactive Compound Library
T1777
T5001
Tocris Bioactive Compound Library
7049
External IDs
59
Properties
(calculated by RDKit )
Molecular Weight
539.25
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
5
Aromatic Ring Count
3
cLogP
3.62
TPSA
94.22
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.35
Structural alerts
1
historic compounds (Chemical Probes.org)
Obsolete
Related compounds
Custom attributes
(extracted from source data)
Target
FGFR1
FGFR2
FGFR3
FLT1
FLT3
KDR
PDGFRA
PDGFRB
FGFR
LCK
PDGFR
PDGFRα
PDGFRβ
VEGFR
VEGFR1
VEGFR2
VEGFR3
PDGFR¦Á/¦Â
PDGFR¦Á
PDGFR¦Â
FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB
RTK inhibitor
FGFR,PDGFR,Src,VEGFR
FGFR,PDGFR,VEGFR
FLT4
Lyn
SRC
Compound status
clinical
Targets
FLT1,KDR,FLT4,FGFR1,FGFR2,FGFR3,PDGFRA,PDGFRB
MOA
FLT
Src
Inhibitor
FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Indication
idiopathic pulmonary fibrosis (IPF)
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Recommended Cell Concentration
None
Source data